Abstract
A pharmacophore integration strategy was utilized to develop the first co-donor of formaldehyde and nitric oxide (FANO), composed of urotropine derived nitramine/nitrosamine. FANO simultaneously generated formaldehyde and nitric oxide on-demand, resulting in synergistic anticancer effects. Importantly, liposomal formulation of FANO effectively inhibited tumor growth with minimal side-effects, providing a potent combined nitric oxide therapy for malignancy.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemical synthesis
-
Antineoplastic Agents / therapeutic use*
-
Apoptosis / drug effects
-
Cell Line, Tumor
-
Cell Proliferation / drug effects
-
Dose-Response Relationship, Drug
-
Drug Carriers / chemistry
-
Formaldehyde / metabolism*
-
Liposomes / chemistry
-
Methenamine / chemistry
-
Mice
-
Neoplasms / drug therapy*
-
Nitric Oxide / metabolism*
-
Nitric Oxide Donors / chemical synthesis
-
Nitric Oxide Donors / therapeutic use*
-
Nitrosamines / chemical synthesis
-
Nitrosamines / therapeutic use
-
Polyamines / chemical synthesis
-
Polyamines / therapeutic use*
Substances
-
Antineoplastic Agents
-
Drug Carriers
-
Liposomes
-
Nitric Oxide Donors
-
Nitrosamines
-
Polyamines
-
Formaldehyde
-
Nitric Oxide
-
Methenamine